DOCSLIB.ORG

Genetics of Androgen Disposition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetics of Androgen Disposition From the Department of Laboratory Medicine Division of Clinical Pharmacology Karolinska Institutet, Stockholm, Sweden GENETICS OF ANDROGEN DISPOSITION - Implications for Doping Tests Jenny Jakobsson Schulze Stockholm 2007 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. © Jenny Jakobsson Schulze, 2007 ISBN 978-91-7357-397-9 Printed by 2007 Gårdsvägen 4, 169 70 Solna One must sit down before truth without preconception, like a little child, and follow where the facts lead- or one will learn nothing. Thomas Huxley (1825-1895) To Joe and Dante ABSTRACT Anabolic androgenic steroids (AAS) are derivatives of testosterone. Doping with AAS is a severe challenge to the vision, moral and ethics in sports and has also become an increasing problem in society. Testosterone abuse is conventionally assessed by the urinary testosterone glucuronide/ epitestosterone glucuronide (T/E) ratio, levels above 4.0 being considered suspicious. However, there is a large inter-individual variation in testosterone glucuronide and epitestosterone glucuronide excretion, which challenges the accuracy of the test. There are reasons to believe that genetic variation is the single most important cause of variation in disposition of many androgenic compounds. Twin studies in men have demonstrated heritability estimates of 85% and 96% for production rates of testosterone and dihydrotestosterone, respectively. The primary aim of this thesis was to investigate the contribution of genetic components to inter-individual variation in androgen disposition. We found that a deletion polymorphism in the UGT2B17 gene was strongly associated with the urinary testosterone glucuronide levels. All individuals homozygous for the deletion had negligible amounts of urinary testosterone glucuronide. It is a common polymorphism with an allele frequency of 29 % in Swedes and 78 % in Koreans. After a single dose of 360 mg testosterone, 40 % of the subjects homozygous for the UGT2B17 deletion never reached the T/E cut off ratio of 4.0. We showed that the sensitivity and specificity of the T/E test could be markedly improved by using genotype-based cut off ratios. A CYP17 T>C promoter polymorphism was associated with urinary epitestosterone glucuronide levels and consequently the T/E ratio. High natural T/E ratios due to low urinary levels of epitestosterone glucuronide may be partly explained by this polymorphism. Considering only individuals with a functional UGT2B17 enzyme, carriers of the CYP17 TT genotype exhibited 64 % higher T/E ratios than men with one or two C-alleles. The frequency of the TT genotype was 35 % in Caucasians. Another polymorphism (E77G) in 17E-hydroxysteroid dehydrogenase type 5 (HSD17B5), an enzyme that catalyses the step between androstenedione and testosterone, was associated with serum testosterone levels in Caucasian men. Considering only individuals with a functional UGT2B17 enzyme, this polymorphism was also associated with urinary testosterone glucuronide levels. The polymorphism had an allele frequency of 4.8 % in Swedes but was completely absent in Koreans. We also found a novel functional promoter polymorphism in the CYP7B1 gene, which was associated with significantly higher promoter activity and had an allele frequency of 4 % in Swedes and 0.65 % in Koreans. In summary, genetic variation has a large impact on androgen disposition. This variation is of the utmost importance for the interpretation of doping test results. The role of this variation for diseases in steroid target organs or for endocrine adverse reactions to drugs remains to be elucidated. LIST OF PUBLICATIONS I. Jakobsson J, Karypidis H, Johansson J. E, Roh H. K, Rane A, Ekstrom L. A functional C-G polymorphism in the CYP7B1 promoter region and its different distribution in Orientals and Caucasians. Pharmacogenomics J. 2004; 4:245-50 II. Jakobsson J, Palonek E, Lorentzon M, Ohlsson C, Rane A, Ekstrom L. A novel polymorphism in the 17beta-hydroxysteroid dehydrogenase type 5 (aldo-keto reductase 1C3) gene is associated with lower serum testosterone levels in caucasian men. Pharmacogenomics J 2007; 7:282-9 III. Jakobsson J, Ekstrom L, Inotsume N, Garle M, Lorentzon M, Ohlsson C, Roh H. K, Carlstrom K, Rane A. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab. 2006; 91:687-93 IV. Jakobsson Schulze J, Lundmark J, Garle M, Skilving I, Ekström L, Rane A. Doping test results dependent on the major enzyme (UGT2B17) for testosterone glucuronidation. Submitted to J Clin Endocrinol Metab. V. Jakobsson Schulze J, Lorentzon M, Ohlsson C, Lundmark J, Roh H. K, Rane A and Ekström L. Genetic aspects of epitestosterone formation and androgen disposition; Influence of polymorphisms in CYP17 and UGT2B enzymes. Submitted to Pharmacogenetics and Genomics Related Work: Eriksson AL, Lorentzon M, Mellstrom D, Vandenput L, Swanson C, Andersson N, Hammond GL, Jakobsson J, Rane A, Orwoll ES, Ljunggren O, Johnell O, Labrie F, Windahl SH, Ohlsson C 2006 SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab 91:5029-37 Swanson C, Lorentzon M, Vandenput L, Labrie F, Rane A, Jakobsson J, Chouinard S, Belanger A, Ohlsson C 2007 Sex Steroid Levels and Cortical Bone Size in Young Men is Associated with a Glucuronidation Enzyme UGT2B7 Polymorphism (H268Y). J Clin Endocrinol Metab Sep;92(9):3697-704 Swanson C, Mellstrom D, Lorentzon M, Vandenput L, Jakobsson J, Rane A, Karlsson M, Ljunggren O, Smith U, Eriksson AL, Belanger A, Labrie F, Ohlsson C 2007 The UDP Glucuronosyltransferase 2B15 D85Y and 2B17 Deletion Polymorphisms Predict the Glucuronidation Pattern of Androgens and Fat Mass in Men. J Clin Endocrinol Metab Aug 14; [Epub ahead of print] CONTENTS 1 INTRODUCTION 1 1.1 General introduction 1 1.2 Endogenous Androgens and doping 1 1.2.1 Testosterone 1 1.2.1.1 Adverse effects 3 1.2.2 Epitestosterone 4 1.2.3 Dihydrotestosterone 6 1.3 Doping in Society 7 1.4 Genetic variability 8 1.4.1 The Androgen receptor 8 1.4.2 Steroid binding proteins 9 1.4.3 Testosterone metabolizing enzymes 9 1.4.3.1 CYP17 9 1.4.3.2 3ȕ-HSD 10 1.4.3.3 17ȕ-HSD 10 1.4.3.4 AKR1C 11 1.4.3.5 5Į-reductase 12 1.4.3.6 CYP7B1 12 1.4.3.7 CYP19 13 1.4.4 Androgen- Phase II enzymes 13 1.4.4.1 Sulfotransferases 13 1.4.4.2 Glucuronosyl transferases 14 1.4.5 The UDP-glucuronosyltransferase 2B subfamily 14 1.4.5.1 UGT2B7 15 1.4.5.2 UGT2B15 16 1.4.5.3 UGT2B17 16 2 THE PRESENT STUDY 17 2.1 Aims 17 2.2 Methods 18 2.2.1 Subjects 18 2.2.2 In silico and in vitro identification of polymorphisms 19 2.2.3 Microsome and cytosol preparation 19 2.2.4 In vitro incubations 20 2.2.5 Serum analyses 20 2.2.6 Urine analyses 21 2.2.7 GC-MS analyses 21 2.2.8 HPLC-analysis 22 2.2.9 Genotyping 22 2.2.10 Reporter gene assay 23 2.2.11 Recombinant enzyme expression 23 2.3 Results and Discussion 24 2.3.1 Paper I: A functional C-G polymorphism in the CYP7B1 promoter region and its different distribution in Orientals and Caucasians 24 2.3.2 Paper II: A novel polymorphism in the 17E-hydroxysteroid dehydrogenase type 5 (aldo-keto reductase 1C3) gene is associated with lower serum testosterone levels in Caucasian men 25 2.3.2.1 Preliminary results 26 2.3.3 Paper III: Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism 27 2.3.3.1 Preliminary results 29 2.3.4 Paper IV: Doping test results dependent on the major enzyme (UGT2B17) for testosterone glucuronidation 30 2.3.4.1 Preliminary results 32 2.3.5 Paper V: Genetic aspects of epitestosterone formation and androgen disposition; influence of polymorphisms in CYP17 and UGT2B enzymes 34 2.3.5.1 Preliminary results 36 3 GENERAL DISCUSSION AND FUTURE CONSIDERATIONS 38 4 SUMMARY 40 5 POPULAR SCIENCE SUMMARY 41 5.1 Populärvetenskaplig sammanfattning 42 6 ACKNOWLEDGEMENTS 44 7 REFERENCES 46 LIST OF ABBREVIATIONS AAS Anabolic androgenic steroids Aa-3D-diol 5D-Androstane-3D,17E-diol Aa-3E-diol 5D-Androstane-3E,17E-diol ADT Anti-doping test Ae-17D-diol 5-Androstene-3D,17E-diol AKR Aldoketo reductase AR Androgen receptor CYP Cytochrome P450 DHEA Dehydroepiandrosterone DHT Dihydrotestosterone EG Epitestosterone glucuronide EMSA Electrophoretic mobility shift assay ER Estrogen receptor ES Epitestosterone sulfate EST Expressed sequence tag HSD Hydroxysteroid dehydrogenase IOC International Olympic committee LH Luteinizing hormone NST Non SHBG-bound testosterone PCR Polymerase chain reaction RIA Radioimmunoassay RQ Relative quantification SHBG Steroid hormone binding protein SNP Single nucleotide polymorphism SSCP Single strand conformational polymorphism SULT Sulfotransferase T/E ratio Testosterone/epitestosterone ratio TG Testosterone glucuronide TS Testosterone sulfate UGT UDP-glucuronosyltransferase WADA World Anti-Doping Agency 1 INTRODUCTION 1.1 GENERAL INTRODUCTION There are reasons to believe that genetic variation is the single most important cause of variation in disposition of many androgenic compounds. The conjugating enzyme systems such as the uridine diphosphoglucuronosyl transferases (UGT) and sulfate conjugases are the major determinants of steroid disposition. As will be shown in this thesis, the genetic variation has a marked impact on turnover and excretion of androgens. Elucidation of the impact of genetic variability on the formation and excretion of androgens is important to increase our understanding of the role of these hormones in the pathology of endocrine organs. Doping with natural or exogenous androgen derivatives is a severe challenge to the vision, moral and ethics of sports all over the world.
Load more

Recommended publications
  • Steroid Profiling in Urine of Intact Glucuronidated and Sulfated
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Ghent University Academic Bibliography Journal of Chromatography A 1624 (2020) 461231 Contents lists available at ScienceDirect Journal of Chromatography A journal homepage: www.elsevier.com/locate/chroma Steroid profiling in urine of intact glucuronidated and sulfated steroids using liquid chromatography-mass spectrometry ∗ Laurie De Wilde , Kris Roels, Pieter Van Renterghem, Peter Van Eenoo, Koen Deventer 1 Doping Control Laboratory (DoCoLab), Ghent University (UGent), Department Diagnostic Sciences, Technologiepark 30B, B-9052 Zwijnaarde, Belgium a r t i c l e i n f o a b s t r a c t Article history: Detection of endogenous anabolic androgenic steroids (EAAS) misuse is a major challenge in doping con- Received 26 November 2019 trol analysis. Currently, a number of endogenous steroids, which constitute the steroid profile, are quanti- Revised 6 May 2020 fied using gas chromatography (GC). With this methodology, only the sum of the free and glucuronidated Accepted 10 May 2020 steroids is measured together. A dilute-and-shoot LC-MS method, which is compliant with the quality Available online 23 May 2020 requirements for measuring EAAS established by the World Anti-Doping Agency (WADA), was devel- Keywords: oped and validated containing glucuronidated and sulfated steroids in order to gain some extra infor- Doping mation and to expand the existing steroid profile. The developed method is, to the best of our knowl- Urine edge, the first method to combine both steroid glucuronides and sulfates, which is compliant with the Steroid profile quality standards of the technical document on EAAS, established by WADA.
    [Show full text]
  • Test Report Comprehensive Hormone Insights™
    698814 COMPREHENSIVE HORMONE INSIGHTS™ TEST REPORT Dr. Maximus, N.D. E: [email protected] Date of Collection: P: 403-241-4500 Time of Collection: F: 403-241-4501 Date of Receipt: www.rmalab.com Reported On: CHI Accession: 698814 Healthcare Professional Patient Age: Dr. Maximus, N.D. Date of Birth: Gender: Male F: Relevant Medications Biometrics Curcumin Height (in) : 73 Weight (lb) : 180 BMI : 24 Waist (in) : 35 Hip (in) : 41 CHI Accession: 698814 SUMMARY HMUS01 How to read the graphs LEGEND: 50 66 Sex Steroid Hormones 50 66 Middle third of 33 33 84 reference population Hormone Start of 83 100 80 100 highest 16 Percentile Precursors 16 Percentile third of Sum of Androgens Sum of Estrogens 50 66 reference 0 0 population (T, DHT, α+β androstanediol) Listed in Interp Guide 33 84 End of 100 16 lowest Percentile00 50 66 50 66 third of 33 33 84 reference 0 population Patient’s percentile rank 81 100 95 100 compared to reference 16 Percentile 16 Percentile population (see summary) DHEA + Metabolites Sum of Progesterone Metabolites 0 (DHEA + A + E) 0 α+β Pregnanediol Cortisol Melatonin Oxidative Stress Free Cortisol Profile (ng/mg) 100 50 66 50 66 33 84 33 84 80 64 100 0 100 16 Percentile 16 Percentile 60 6-sulfatoxy 8-Hydroxy-2- 0 Melatonin 0 deoxyguanosine 40 (Overnight) (Overnight) 20 6-sulfatoxymelatonin provides 8-hydroxy-2-deoxyguanosine is Cortisol/Creatinine (ng/mg) insight into melatonin levels. a marker of oxidative stress 0 Morning Dinner Bedtime A B C 50 66 Free cortisol Cortisol Metabolites 33 84 profile is used to provides a general Testosterone Cortisol assess diurnal assessment of 16 100 cortisol rhythm adrenal cortisol 16 Percentile Cortisol production Cortisol Metabolites 0 (α+β THF + THE) Testosterone Cortisol/Testosterone provides insight into relative catabolic (cortisol) and anabolic (testosterone) states.
    [Show full text]
  • Normal Steroid Levels in Racehorses (Print) Page 1 of 2
    The Horse | Normal Steroid Levels in Racehorses (print) Page 1 of 2 Normal Steroid Levels in Racehorses by: Christy West February 28 2010 Article # 15889 Steroid usage in racehorses has received a good deal of attention in the media, perhaps reaching a peak during the 2009 Triple Crown season when Big Brown won the Kentucky Derby and Preakness on the legally administered steroid stanozolol, then flopped in the Belmont without it. While no one could ever prove the steroid helped the horse win or that his loss was associated with being steroid-free, the situation added significant fuel to the fire of medication regulation in racehorses. One of the tough aspects of regulating substances that are naturally produced in the horse's body, such as many steroids, is that before you can decide how high a level of the substance constitutes an administered medication or abuse, you have to find out how much horses produce normally. At the 2009 American Association of Equine Practitioners (AAEP) Convention held Dec. 5-9 in Las Vegas, Nev., one presenter discussed a study that sought to answer that question for anabolic androgenic steroids (hormones that stimulate masculine physical characteristics) in young Thoroughbreds. Currently there are four anabolic androgenic steroids commonly used therapeutically in racehorses: Stanozolol, nandrolone, testosterone, and boldenone, said presenter Benjamin C. Moeller, BS, a graduate student at the K.L. Maddy Equine Analytical Chemistry Laboratory at the University of California, Davis. In collaboration with veterinarians at Rood & Riddle Equine Hospital and Hagyard Equine Medical Institute (both in Lexington, Ky.), and Craig Van Balen (private practitioner in Lexington), 142 un-medicated Thoroughbred colts and 62 fillies in training at Central Kentucky farms, from five to 24 months of age, were blood tested monthly for 13 months.
    [Show full text]
  • Development and Application of Methods for Extraction and LC/MS/MS Analysis of Sex Steroids and Conjugates from Fish Feces
    Development and Application of Methods for Extraction and LC/MS/MS Analysis of Sex Steroids and Conjugates from Fish Feces By Lisa E. Peters A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements of the degree of Doctor of Philosophy Department of Environment and Geography University of Manitoba Winnipeg Copyright © 2014 Lisa E. Peters 1 Acknowledgments I would like to start by thanking my supervisor, Dr. Gregg Tomy, for his support, patience and resources during my Ph.D. program. He took a chance when I tried to convince him that my biology background would be a great addition to his chemistry lab. My husband, Vince Palace, and I also appreciated his support and genuine happiness for us when I announced we were expecting a baby in the middle of my studies. A sincere thanks also goes to my co-supervisor, Dr. Mark Hanson, for his support on so many levels (I wouldn’t even know where to start), and for doing his best to keep me on track, which was no small task. I would also like to thank my other thesis committee members, Drs. Gary Anderson and Feiyue Wang, for their encouragement and insightful comments. Gary gave a lot of extra time to review various thesis chapters and data, and to lend his expertise during the fish surgeries. I also had the pleasure of taking his Endocrinology course, which was probably the most informative and enjoyable class of my entire university student career. I would like to thank the technical staff and students from DFO, Suzanne Mittermuller, Kerry Wautier, Alea Goodmanson, Danielle Godard, Lisa Friedrich and Kirstin Dangerfield, and my lab mates Bruno Rosenberg, Kerri Pleskach, Colin Darling, Bonnie Gemmill and Lianna Bestvater for their technical input and help during my experiments.
    [Show full text]
  • Hormone Testing Summary All Units Are Given in Ng/Mg Creatinine
    Accession # 00212403 Sample Female Report 123 A Street Sometown, CA 90266 Collection Times: Ordering physician: DOB:1976-01-01 2015-08-16 05:00PM 2015-08-16 10:00PM Precision Analytical Gender: Female 2015-08-17 06:00AM 2015-08-17 08:00AM Hormone Testing Summary All units are given in ng/mg creatinine Sex Hormones See Pages 2 and 3 for a thorough breakdown of sex hormone metabolites opausa n l R e a m n e r g P e your 27.0 62.0 6.0 4.0 14.0 low limit high limit 80.5 17.9 12.8 result Postmenopausal 20.0 range 6.0-17.0 0.3-2.0 Total Estrogen Progesterone Testosterone How to read the graphical (Sum of 8 Estrogen Metabolites) (Serum Equivalent, ng/mL) representation of results Progesterone Serum Equivalent is a calculated value based on urine pregnanediol. This value may not accurately reflect serum when progesterone is taken by mouth. Adrenal Hormones See pages 4 and 5 for a more complete breakdown of adrenal hormones Total DHEA Production 100 High Range Limit 400.0 2500.0 ) 2218.0 g Age Range m Daily Free Cortisol Pattern / g 20-40 800-2500 n 80 ( 40-60 530-1550 Total DHEA Production l >60 400-1350 (DHEAS + Etiocholanolone + Androsterone) o s 60 i t r o C 40 2240.0 4300.0 Patient Values Low Range Limit 80.0 48.0 180.0 5033.0 20 24hr Free Cortisol cortisol Metabolized Cortisol (THF+THE) 0 (A+B+C+D) metabolism (Total Cortisol Production) Waking (A) Morning (B) Afternoon (C) Night (D) Free cortisol best reflects tissue levels.
    [Show full text]
  • Metabolism of Testoterone and Related Steroids in Metastatic Interstitial Cell Carcinoma of the Testis
    Metabolism of testoterone and related steroids in metastatic interstitial cell carcinoma of the testis. M B Lipsett, … , C W Bardin, L M Fishman J Clin Invest. 1966;45(11):1700-1709. https://doi.org/10.1172/JCI105476. Research Article Find the latest version: https://jci.me/105476/pdf Journal of Clinical Investigation Vol. 45, No. 11, 1966 Metabolism of Testosterone and Related Steroids in Metastatic Interstitial Cell Carcinoma of the Testis * M. B. LIPSETT,t G. A. SARFATY, H. WILSON, C. WAYNE BARDIN, AND L. M. FISHMAN (From the Endocrinology Branch, National Cancer Institute, Bethesda, Md.) Interstitial cell carcinoma of the testis is a singu- production rate has been shown to be a conse- larly rare steroid-producing cancer. Of the seven quence of metabolism of dehydroepiandrosterone reported cases (1-7), urinary 17-ketosteroid (17- sulfate. KS) excretion was high in the four cases in which it was measured. Abelson, Bulaschenko, Trom- Methods mer, and Valdes-Dapena (7) fractionated the uri- Routine methods were used to analyze the following: nary 17-ketosteriods and corticoids in one recently urinary 17-KS (8), urinary 17-hydroxycorticoids (9), reported case. There is, however, no comprehen- plasma Silber-Porter chromogens (10), and plasma tes- tosterone (11). sive study of either the production of androgens Gas-liquid chromatography. We carried out gas-liquid or related steroids by this tumor. We have had chromatography (GLC) in a Glowell Chromolab gas the opportunity to study a patient with metastatic chromatograph utilizing a 'Sr ionization detector oper- interstitial cell carcinoma, and we have examined ating at 1,050 v.
    [Show full text]
  • Adult Subjects and Patients with Various Endocrine Disorders *
    Journal of Clinical Investigation Vol. 43, No. 6, 1964 Studies on the Origin of Testosterone in the Urine of Normal Adult Subjects and Patients with Various Endocrine Disorders * ALVRO M. CAMACHO t AND CLAUDE J. 'MIGEON (From the Endocrine Clinic of the Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md.) We have recently described a procedure for the lized to testosterone glucuronide. In addition, the isolation of testosterone 1 from human urine after metabolism of testosterone and the quantity ex- P-glucuronidase hydrolysis, indicating that it was creted as unconjugated testosterone, as testosterone conjugated with glucuronic acid (1). We also glucuronide, and as testosterone sulfate was reported on the urinary excretion of testosterone studied. in adult subjects and in patients with endocrine Methods disorders. 1) Preparation of radioactive steroids. 4-C14-testos- The concentration of 17-ketosteroids in bio- terone 2 (SA, 71.43 /Ac per mg), 1,2-H3-testosterone (SA, logical fluids is commonly used as an index of 2.63 mc per mg), 4-C'4-17a-hydroxyprogesterone (SA, virilization. Frequently, however, there is no cor- 43.48 ,uc per mg), 4-C14-androstenedione (SA, 7.58 ,uc per relation between the degree of virilism observed mg), and 7a-H3-dehydroepiandrosterone acetate (SA, in patients and levels of the 17-ketosteroids in 25.65 mc per mg) were used in this investigation. Be- blood fore use, they were purified by paper chromatography or urine. Testosterone could be produced (2). by such patients in amounts sufficient to cause 2) Mode of injection of radioactive steroids and urine virilization without appreciably increasing the collections.
    [Show full text]
  • Disposition and Metabolic Profile of the Weak Androgen
    APPLIED MEDICINE: CLINICAL PATHOLOGY AND DERMATOLOGY Disposition and Metabolic Profile of the Weak Androgen Dehydroepiandrosterone After Administration as Part of a Nutritional Supplement to Exercised Horses Rick M. Arthur, DVM†; Heather K. Knych, DVM, PhD, Diplomate ACVCP*; and Scott D. Stanley, PhD After oral administration of a nutritional supplement containing dehydroepiandrosterone (DHEA), horses are capable of producing detectable levels of testosterone, which can result in a positive regulatory finding. Authors’ addresses: School of Veterinary Medicine (Arthur), K.L. Maddy Equine Analytical Chemistry Laboratory (Knych, Stanley), University of California, Davis, CA 95616; e-mail: [email protected]. *Corresponding author; †presenting author. © 2013 AAEP. 1. Introduction various times up to 48 hours after drug administra- Dehydroepiandrosterone (DHEA) is a weak andro- tion. Plasma concentrations of DHEA, testoster- gen as well as a precursor to the much more potent one, and pregnenolone as well as their sulfated androgen, testosterone. Although DHEA is not conjugates were measured by means of liquid chro- specifically banned from administration to race- matography-mass spectrometry. horses, the potential for metabolism to substances such as testosterone that are not permitted in racing 3. Results and Discussion make its presence in nutritional supplements fed to Peak plasma concentrations of DHEA, DHEA sul- horses a regulatory concern. In the current study, fate, and testosterone sulfate were 10.1 Ϯ 8.84 ng/ we sought to describe the metabolic profile after Ϯ Ϯ administration of a nutritional supplement contain- ml, 25.7 10.2, and 0.670 1.17, respectively. ing precursors to non-permitted androgens to exer- All compounds were below the limit of detection by cised female horses.
    [Show full text]
  • Sex Hormones and Metabolites
    Accession # 00268796 Male Sample Report 123 A Street Sometown, CA 90266 Sex Hormones and Metabolites Ordering Physician: DOB: 1967-08-09 Collection Times: Precision Analytical Age: 50 2017-08-09 06:01AM 2017-08-09 08:01AM Gender: Male 2017-08-09 05:01PM 2017-08-09 10:01PM Category Test Result Units Normal Range Progesterone Metabolites (Urine) b-Pregnanediol Low end of range 110.0 ng/mg 75 - 400 a-Pregnanediol Low end of range 40.0 ng/mg 20 - 130 Estrogens and Metabolites (Urine) Estrone(E1) High end of range 15.3 ng/mg 4 - 16 Estradiol(E2) Above range 2.4 ng/mg 0.5 - 2.2 Estriol(E3) Within range 4.2 ng/mg 2 - 8 2-OH-E1 Within range 3.73 ng/mg 0 - 5.9 4-OH-E1 Above range 1.2 ng/mg 0 - 0.8 16-OH-E1 Within range 0.7 ng/mg 0 - 1.2 2-Methoxy-E1 Within range 2.1 ng/mg 0 - 2.8 2-OH-E2 Above range 0.61 ng/mg 0 - 0.6 4-OH-E2 Within range 0.2 ng/mg 0 - 0.3 2-Methoxy-E2 Within range 0.6 ng/mg 0 - 0.8 Total Estrogen High end of range 30.3 ng/mg 10 - 34 Androgens and Metabolites (Urine) DHEA-S Low end of range 95.0 ng/mg 30 - 1500 Androsterone Low end of range 835.0 ng/mg 500 - 3000 Etiocholanolone Below range 387.0 ng/mg 400 - 1500 Testosterone Below range 21.6 ng/mg 25 - 115 5a-DHT Low end of range 8.2 ng/mg 5 - 25 5a-Androstanediol Low end of range 52.0 ng/mg 30 - 250 5b-Androstanediol Low end of range 46.0 ng/mg 40 - 250 Epi-Testosterone Low end of range 38.1 ng/mg 25 - 115 Precision Analytical (Dawn Huo, Ph.D., Lab Director) Male Sample Report Page 1 of 9 3138 Rivergate Street #301C FINAL REPORT CLIA Lic.
    [Show full text]
  • Download (1MB)
    Essays in Biochemistry (2020) EBC20200043 https://doi.org/10.1042/EBC20200043 Review Article Biosynthesis and signalling functions of central and peripheral nervous system neurosteroids in health and disease Downloaded from https://portlandpress.com/essaysbiochem/article-pdf/doi/10.1042/EBC20200043/889583/ebc-2020-0043c.pdf by UK user on 01 September 2020 Emyr Lloyd-Evans1 and Helen Waller-Evans2 1Sir Martin Evans Building, School of Biosciences, Cardiff University, Museum Avenue, Cardiff, CF10 3AX, U.K.; 2Medicines Discovery Institute, Main Building, Cardiff University, Park Place, Cardiff, CF10 3AT, U.K. Correspondence: Emyr Lloyd-Evans ([email protected]) or Helen Waller-Evans ([email protected]) Neurosteroids are steroid hormones synthesised de novo in the brain and peripheral nervous tissues. In contrast to adrenal steroid hormones that act on intracellular nuclear receptors, neurosteroids directly modulate plasma membrane ion channels and regulate intracellular signalling. This review provides an overview of the work that led to the discovery of neu- rosteroids, our current understanding of their intracellular biosynthetic machinery, and their roles in regulating the development and function of nervous tissue. Neurosteroids mediate signalling in the brain via multiple mechanisms. Here, we describe in detail their effects on GABA (inhibitory) and NMDA (excitatory) receptors, two signalling pathways of opposing function. Furthermore, emerging evidence points to altered neurosteroid function and sig- nalling in neurological disease. This review focuses on neurodegenerative diseases associ- ated with altered neurosteroid metabolism, mainly Niemann-Pick type C, multiple sclerosis and Alzheimer disease. Finally, we summarise the use of natural and synthetic neurosteroids as current and emerging therapeutics alongside their potential use as disease biomarkers.
    [Show full text]
  • OATP-Mediated Hepatic Uptake of Glucuronide Metabolites of Androgens
    Molecular Pharmacology Fast Forward. Published on June 25, 2020 as DOI: 10.1124/mol.120.119891 This article has not been copyedited and formatted. The final version may differ from this version. MOL#119891 Title Page OATP-mediated hepatic uptake of glucuronide metabolites of androgens Cindy Yanfei Li, Anshul Gupta, Zsuzsanna Gáborik, Emese Kis, and Bhagwat Prasad* Department of Pharmaceutics, University of Washington, Seattle, WA, USA (CYL) Downloaded from Amgen Research, Department of Pharmacokinetics and Drug Metabolism, Cambridge, MA, USA 02142 (AG) molpharm.aspetjournals.org SOLVO Biotechnology, Budapest, Hungary (ZG and EK) Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, USA (BP) at ASPET Journals on September 29, 2021 1 Molecular Pharmacology Fast Forward. Published on June 25, 2020 as DOI: 10.1124/mol.120.119891 This article has not been copyedited and formatted. The final version may differ from this version. MOL#119891 Running Title Page Running title: Hepatic uptake of glucuronide metabolites of androgens *To whom correspondence should be addressed: Bhagwat Prasad, Ph.D., Department of Pharmaceutical Sciences, Washington State University, 412 E Spokane Falls Blvd, Spokane, WA 99202, Email: [email protected]. Phone: 509-358-7739; Fax: 509-368-6561. Downloaded from Number of text pages: 34 Number of tables: 2 molpharm.aspetjournals.org Number of figures: 4 Number of references: 51 at ASPET Journals on September 29, 2021 Number of words in the Abstract: 246 Number of words in the Introduction:
    [Show full text]
  • Sex Hormones and Metabolites
    Accession # 00268796 Male Sample Report 123 A Street Sometown, CA 90266 Sex Hormones and Metabolites Ordering Physician: DOB: 1967-08-09 Collection Times: Precision Analytical Age: 50 2017-08-09 06:01AM 2017-08-09 08:01AM Gender: Male 2017-08-09 05:01PM 2017-08-09 10:01PM Category Test Result Units Normal Range Progesterone Metabolites (Urine) b-Pregnanediol Low end of range 110.0 ng/mg 75 - 400 a-Pregnanediol Low end of range 40.0 ng/mg 20 - 130 Estrogens and Metabolites (Urine) Estrone(E1) High end of range 15.3 ng/mg 4 - 16 Estradiol(E2) Above range 2.4 ng/mg 0.5 - 2.2 Estriol(E3) Within range 4.2 ng/mg 2 - 8 2-OH-E1 Within range 3.73 ng/mg 0 - 5.9 4-OH-E1 Above range 1.2 ng/mg 0 - 0.8 16-OH-E1 Within range 0.7 ng/mg 0 - 1.2 2-Methoxy-E1 Within range 2.1 ng/mg 0 - 2.8 2-OH-E2 Above range 0.61 ng/mg 0 - 0.6 4-OH-E2 Within range 0.2 ng/mg 0 - 0.3 2-Methoxy-E2 Within range 0.6 ng/mg 0 - 0.8 Androgens and Metabolites (Urine) DHEA-S Low end of range 95.0 ng/mg 30 - 1500 Androsterone Low end of range 835.0 ng/mg 500 - 3000 Etiocholanolone Below range 387.0 ng/mg 400 - 1500 Testosterone Below range 21.6 ng/mg 25 - 115 5a-DHT Low end of range 8.2 ng/mg 5 - 25 5a-Androstanediol Low end of range 52.0 ng/mg 30 - 250 5b-Androstanediol Low end of range 46.0 ng/mg 40 - 250 Epi-Testosterone Low end of range 38.1 ng/mg 25 - 115 Precision Analytical (Raymond Grimsbo, Lab Director) Male Sample Report Page 1 of 6 3138 Rivergate Street #301C FINAL REPORT CLIA Lic.
    [Show full text]